Sage Journals: Discover world-class research

Abstract

Background:

There is interest in using bladder-preserving therapy as an alternative definitive therapy for muscle invasive bladder cancer in certain high-risk groups such as the elderly.

Objective:

To determine if bladder-preserving therapy represents a safer alternative to surgical intervention in elderly patients with muscle invasive bladder cancer.

Methods:

We surveyed the Surveillance, Epidemiology and End Results database (SEER) for cases of non-metastasized malignant bladder cancer in patients aged 80+. Survival outcomes with radical cystectomy (RC) with or without chemotherapy were compared to those after chemotherapy and radiation without cystectomy. We performed log-rank tests and Kaplan-Meier and cox regression and hazard analyses before and after propensity score matching.

Results:

A total of 2995 patients were identified, with 49.98% treated with RC only, 8.65% treated with RC/chemotherapy, and 41.37% treated with chemotherapy and radiation without RC. Median overall survival for the RC only, RC/chemotherapy and chemotherapy/radiation groups were 31.4, 44.1, and 24.6 months, respectively. On multivariate analysis, hazard ratios (reference: RC/chemotherapy group) were RC Only (HR = 1.408 (95% CI 1.188–1.669), p < 0.0001) and chemotherapy/radiation (HR = 1.650 (95% CI 1.390–1.959), p < 0.0001). After matching the chemotherapy/radiation and RC/chemotherapy groups, the former continued to show survival hazard (HR = 1.744 (95% CI 1.414–2.155), p < 0.0001).

Conclusions:

Octogenarians should be offered definitive local therapy for their localized bladder cancer including RC and chemotherapy. Bladder-sparing alternatives should be reserved for patients unfit for surgery.

Keywords

Bladder cancer octogenarian cystectomy chemotherapy

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7–30.

Lin

Kernen

, et al National Cancer Database comparison of radical cystectomy vs chemoradiotherapy for muscle-invasive bladder cancer: implications of using clinical vs pathologic staging. Cancer Med 2018; 7(11): 5370–5381.

Miller

Nogueira

Mariotto

, et al Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69(5): 363–385.

Kozak

Hamidi

Manning

, et al Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83(2): e197–e204.

Cahn

Handorf

Ghiraldi

, et al Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer 2017; 123(22): 4337–4345.

Zietman

Sacco

Skowronski

, et al Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170(5): 1772–1776.

Henningsohn

Wijkström

Dickman

, et al Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2002; 62(2): 215–225.

SAS Institute Inc. Sas/stat® 14.2 user’s guide. Cary, NC: SAS Institute Inc, 2016.

Austin

. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46(3): 399–424.

10.

Sanli

Dobruch

Knowles

, et al Bladder cancer. Nat Rev Dis Primers 2017; 3: 17022.

11.

Fedeli

Fedewa

Ward

. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 2011; 185(1): 72–78.

12.

Turrentine

Wang

Simpson

, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006; 203(6): 865–877.

13.

Freedman

Silverman

Hollenbeck

, et al. Association between smoking and risk of bladder cancer among men and women [published correction appears in JAMA. 2011 Nov 23;306(20):2220]. JAMA 2011; 306(7): 737–745.

14.

Spiess

Agarwal

Bangs

, et al Bladder Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15(10): 1240–1267.

15.

Mak

Hunt

Shipley

, et al Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; 32(34): 3801–3809.

16.

Huddart

Birtle

Lewis

, et al Results of the SPARE feasibility study – selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder (CRUK/07/011). Int J Radiat Oncol Biol Phys 2012; 84(3): S119–S120.

17.

Efstathiou

Spiegel

Shipley

, et al Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012; 61(4): 705–711.

18.

Royce

Feldman

Mossanen

, et al Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2019; 17(1): 23–31.e3.

19.

Natale

Leinwand

Zeineddine

, et al Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study. Cancer Treat Res Commun 2020; 24: 100177.

20.

Danesi

Arcangeli

Cruciani

, et al Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 2004; 101(11): 2540–2548.

21.

Gakis

Efstathiou

Lerner

, et al; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU international consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63(1): 45–57.

22.

Chang

Bochner

Chou

, et al Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline [published correction appears in J Urol. 2017 Nov;198(5):1175]. J Urol 2017; 198(3): 552–559.

23.

Natale

Leinwand

Chiang

, et al Reviewing the demographic, prognostic, and treatment factors of primary adenocarcinoma of the bladder: a SEER population-based study. Clin Genitourin Cancer 2019; 17(5): 380–388.

24.

Fischer-Valuck

Rao

Rudra

, et al Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the National Cancer Database. J Urol 2018; 199(2): 416–423.

25.

Krane

Richards

Kader

, et al Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol 2013; 27(8): 1046–1050.

26.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Gov). SEER*Stat Database: Incidence - SEER Research Data, Database 18, Nov 2019 Sub (1975-2016) - released April 2020, based on the November 2019 submission.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Assessing the safety of bladder-preserving therapy as an alternative to surgical intervention in elderly patients with muscle invasive bladder cancer